

INFERTILITY

Absence of sperm RNA elements correlates with idiopathic male infertility

Meritxell Jodar,^{1,2} Edward Sendler,^{1,2} Sergey I. Moskvovtsev,^{3,4} Clifford L. Librach,^{3,4,5} Robert Goodrich,^{1,2} Sonja Swanson,³ Russ Hauser,^{6,7} Michael P. Diamond,⁸ Stephen A. Krawetz^{1,2*}

Semen parameters are typically used to diagnose male infertility and specify clinical interventions. In idiopathic infertile couples, an unknown male factor could be the cause of infertility even when the semen parameters are normal. Next-generation sequencing of spermatozoal RNAs can provide an objective measure of the paternal contribution and may help guide the care of these couples. We assessed spermatozoal RNAs from 96 couples presenting with idiopathic infertility and identified the final reproductive outcome and sperm RNA elements (SREs) reflective of fecundity status. The absence of required SREs reduced the probability of achieving live birth by timed intercourse or intrauterine insemination from 73 to 27%. However, the absence of these same SREs does not appear to be critical when using assisted reproductive technologies such as in vitro fertilization with or without intracytoplasmic sperm injection. About 30% of the idiopathic infertile couples presented an incomplete set of required SREs, suggesting a male component as the cause of their infertility. Conversely, analysis of couples that failed to achieve a live birth despite presenting with a complete set of SREs suggested that a female factor may have been involved, and this was confirmed by their diagnosis. The data in this study suggest that SRE analysis has the potential to predict the individual success rate of different fertility treatments and reduce the time to achieve live birth.

INTRODUCTION

About 13% of the general reproductive age population have fertility problems (1). The American Society for Reproductive Medicine estimates that male and female factors contribute about equally to this condition, with about one-quarter likely a combination of factors from both partners. After 12 months of unprotected intercourse without pregnancy, affected couples typically begin to seek care and explore the possibility of fertility treatments (2).

More than 1% of the children born in the United States today are conceived using assisted reproductive technologies (ARTs) (3). Typically, to establish the appropriate clinical treatment and minimize the risk of failure, an extensive evaluation of the female, and to a lesser extent the male, is undertaken. If no severe male or female factors are detected, fertility treatments such as timed intercourse (TIC) or intrauterine insemination (IUI) are recommended in combination with ovarian stimulation. After three or four unsuccessful IUI cycles or if a severe male or female factor is detected, in vitro fertilization (IVF) with or without intracytoplasmic sperm injection (ICSI) is typically suggested.

Initial male factor assessment includes a review of reproductive history (time of subfertility, existence of previous pregnancies, and sexual function), family history (consanguinity and infertility history), relevant diseases (diabetes and mumps among others), and exposure to

factors that negatively affect fertility (drugs, life-style, and occupation) along with a comprehensive physical examination. The male contribution is further evaluated by semen analysis, with intra-individual variation gauged through the results of two semen analyses separated by a period of up to 1 month (2). Assessment primarily relies on a defined series of semen parameters that include volume, sperm concentration, sperm motility, and sperm morphology. Other specific measures that may complement the workup include DNA fragmentation, the presence of antisperm antibodies, endocrine status, and genetic and cytogenetic markers such as AZFa or AZFb Y chromosome microdeletions associated with azoospermia. Although the evaluation of general semen parameters like sperm count, motility, and morphology may be useful in the diagnosis of obvious cases of male infertility where specific etiologic factors may be apparent, no single parameter or set of semen parameters are highly predictive of male fertility status within the general population (4). Current clinical practice focuses on whether there are sufficient spermatozoa with satisfactory motility and morphology to reach and likely fertilize the oocyte. Their utility in selecting the least invasive fertility treatment for idiopathic infertile couples appears limited (5).

Spermatozoa are not just a vehicle that delivers the male genomic contribution to the oocyte. Upon fertilization, the spermatozoon provides a complete, highly structured, and epigenetically marked genome that, together with a defined complement of RNAs and proteins, plays a distinct role in early embryonic development (6, 7). Although several studies have explored the effect of genetic variants such as single-nucleotide polymorphisms (SNPs) (8), copy number variants (9), differential genome packaging (10), differential methylation (11), proteomic changes (12), and differential sperm RNAs (13, 14) in male infertility, comparatively few have examined their effect within the context of the reproductive clinic (15–19).

Characterization of the RNAs retained in sperm by next-generation sequencing (NGS) has recently been reported (20–22). In contrast with

¹Department of Obstetrics and Gynecology, Wayne State University, Detroit, MI 48201, USA.

²Center for Molecular Medicine and Genetics, Wayne State University, Detroit, MI 48201, USA.

³CReATe Fertility Centre, Toronto, Ontario M5G 1N8, Canada. ⁴Department of Obstetrics and Gynaecology, University of Toronto, Ontario M5G 1E2, Canada. ⁵Department of Obstetrics and Gynecology, Women's College Hospital, Toronto, Ontario M5G 1B1, Canada.

⁶Vincent Memorial Obstetrics and Gynecology Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA. ⁷Departments of Environmental Health and Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA.

⁸Department of Obstetrics and Gynecology, Georgia Regents University, Augusta, GA 30912, USA.

*Corresponding author. E-mail: steve@compbio.med.wayne.edu

Table 1. Characteristics of the study population. The table details the distribution and characteristics of the study population in relation to fertility treatment used and procedural outcome [LB (live birth) versus NLB (no live birth)]. Group I subjects achieved an LB pregnancy in their first attempt using TIC during the first spermatogenic cycle after semen assessment (90-day cycle) and were considered as a natural conception. Samples from test set II include different subgroups based on treatment: (i) IUI or TIC delayed past the first 90-day cycle, (ii) ART preceded by unsuccessful IUI or TIC, and (iii) ART. The independent set of samples (set III) was composed of two subgroups: (i) samples from an independent fertility clinic, and (ii) patients who never achieved LB and in whom a female factor was subse-

quently diagnosed. Sample characteristics include male and female ages and semen parameters comprising total million sperm cells per sample, sperm motility (%), total motile sperm per sample (TMC), sperm morphology [% of normal forms (NFs)], and sperm DNA fragmentation [DNA fragmentation index (DFI)]. **(A)** The type of fertility treatment used did not correlate with any individual or sperm sample parameter evaluated. **(B)** When all patients were considered as a group, female age showed a negative correlation with LB (two-tailed *t* test, *P* = 0.024). **(C)** Female age was significantly higher in patients who were unsuccessful when treated by ART (two-tailed *t* test, *P* = 0.004) but not in patients who were unsuccessful when treated by TIC/IUI.

A

Group	Natural conception		Test set			Independent set		<i>P</i>
	I		II			III		
Subgroup			i	ii	iii	i	ii	
Male age	35		34.6	33.6	34.2	37	36.2	0.683
Female age	32.3		32	31.1	33.6	35.2	32	0.304
Total million sperm	193.4		172.9	235.8	159	349.9	160.2	0.090
Sperm motility (%)	54		52.3	50	50	39.5	52.5	0.441
TMC	113.9		93.9	125.5	83.8	175.5	86.7	0.342
Sperm morphology (% NF)	10.8		10.6	5.7	9.2	4.5	10.2	0.271
DNA fragmentation (DFI)	14.7		16.4	17.3	19.4	—	18.4	0.734

B

	Final outcome		<i>P</i>
	LB (n = 62)	NLB (n = 10)	
Male age	34.6	35	0.770
Female age	32	34.9	0.024*
Total million sperm	192.4	212.4	0.122
Sperm motility (%)	50.4	52.8	0.583
TMC	103	116.7	0.182
Sperm morphology (% NF)	8.8	10.9	0.342
DNA fragmentation (DFI)	17.5	14.6	0.303

C

	TIC/IUI		<i>P</i>	ART		<i>P</i>
	LB (n = 35)	NLB (n = 17)		LB (n = 27)	NLB (n = 6)	
Female age	32.3	31.5	0.377	31.5	37	0.004*

*Statistically significant differences.

earlier array-based approaches, RNA-seq has revealed a rich and complex population of unique coding and noncoding transcripts such as sperm-specific isoforms, intronic retained and otherwise unannotated elements, and long and small noncoding RNAs (20–22). The large number of unique sperm transcripts is suggestive of regulatory roles (20, 22) influencing fertilization, early embryogenesis, and the phenotype of the offspring (20, 23). The application of spermatozoal microarray-

based approaches to predict the outcome of different fertility treatments has met with varying degrees of success (17, 18). The intricacies of spermatozoal RNAs as revealed by NGS analysis (22) suggest that this technology is much better suited to the task. The objective of this initial study was to evaluate the diagnostic potential of NGS as a prognostic assay of spermatozoal RNAs that can predict the birth outcome after different fertility treatments.

RESULTS

Identifying sperm RNA elements required for natural conception

The ability of spermatozoal RNAs to predict a live birth (LB) outcome for various fertility treatments was assessed within the context of the idiopathic infertile couple to ascertain whether the underlying cause could be attributed to a male factor. As summarized in Table 1A, we observed no significant differences between the choice of treatment modality as a function of the different patient variables including age or any of the semen parameters, consistent with idiopathic infertility [one-tailed analysis of variance (ANOVA) or Kruskal-Wallis test, $P > 0.05$]. Female age was significantly higher in couples that did not achieve pregnancy (Table 1B; two-tailed t test, $P = 0.024$), and this could be attributed to unsuccessful IVF/ICSI (Table 1C; two-tailed t test, $P = 0.004$). We identified a set of sperm RNA elements (SREs) required for LB by natural conception within the positive control group I (LB by TIC during the first spermatogenic cycle and first attempt). Of the 278,605 SREs surveyed, only elements that ranked above the 99th percentile and were essentially at equivalent levels across control group I samples [no outliers outside interquartile range, $IQR \geq 1.5X (Q_3 - Q_1)$] were defined as SREs required for natural conception. A total of 648 elements met these stringent criteria to be classified as required SREs (above the 99th percentile rank, present at a constant level in the control group). Nine of these 648 SREs corresponded to intergenic regions, 12 corresponded to sperm-specific intronic elements, and 42 were within 24 different noncoding RNAs, all of which are likely regulatory. Most (585) were within exonic regions of 262 different genes, 40% of which were ontologically classified as associated with spermatogenesis, sperm physiology, fertility, and early embryogenesis before implantation (Fig. 1).

Ability of SREs to predict fertility treatment outcome

To discern whether SREs were indicative of fertility treatment outcome, a set of 56 samples (group II) from couples that underwent TIC (after the first cycle) or immediately proceeded to IUI or ART was evaluated with respect to the abundance of required SREs defined from group I. As shown in Fig. 2A (left and middle panels), all 648 required SREs were present in the control group of 7 patients and in 37 of the 56 samples within group II (indicated by a color gradient from yellow to green representing the 60th to >90th percentile of abundance). As summarized in Fig. 2B, the samples presenting with all SREs have a 72% (16 of 22) rate of success in achieving an LB within the first two treatment cycles (6 months). In comparison, as shown in Fig. 2A (right panel), 19 group II samples have at least one SRE absent as indicated by the zero percentile-ranked red rectangle (fig.

S1). Although the proportion of male or female factors underlying idiopathic infertility remains to be established, the proportion of patients who were lacking some of the SREs is similar to the expected rate of idiopathic infertility (24, 25). No correlation between the number of SREs absent and semen parameters and age of partners was observed (fig. S2).

Samples with all SREs present have similar high rates of LB for both TIC/IUI and ART, 73% (22 of 30) and 75% (9 of 12), respectively (Fig. 3A). However, the absence of some of the SREs reduced the LB rate by TIC/IUI from 73 to 27% (3 of 11), whereas the LB rate remained similar for ART at 78% (11 of 14; Fig. 3B). As observed in Fig. 3C, patients with all SREs were more likely to achieve LB by TIC/IUI as compared to those with one or more SRE(s) absent (two-tailed Fisher's exact test, $P = 0.012$). These significant differences were supported by a power of 0.7 and α error of 0.029. In comparison, we did not observe any difference in the number of absent SREs when we compared LB and NLB groups after ART treatment (two-tailed Mann-Whitney test, $P = 0.783$). This is consistent with the view that ART may be able to rescue some otherwise impaired sperm functions such as transit to the oocyte and/or fertilization, depending on the functions of the genes corresponding to the missing SREs. Notably, six of the group II couples failed to achieve an LB even by ART. The average female age in this group was significantly higher ($P = 0.004$, two-tailed t test; Table 1C), suggesting a potential age-related female factor, although only three of these six subjects were over 35 years of age. Among the couples that failed to achieve LB by ART with partners ≤ 35 years of age, two did not have a complete set of SREs. The missing SREs were within different genes including *NDRG1* (stress response), *TESK1* (kinase),




Fig. 1. Genomic localization (exon, intron, intergenic, and noncoding RNAs) and function of the 648 required SREs. Most of the required SREs are located in exons of annotated genes (585 of 648; 90.3%), and the remainder are in intronic regions (12 of 648; 1.9%), intergenic regions (9 of 648; 1.4%), or match to noncoding transcriptional elements including small nuclear RNAs, microRNAs, and long noncoding RNAs (42 of 648; 6.5%) with potential regulatory function. About 40% of the genes that contain one or more SREs have a known role in spermatogenesis, sperm physiology (sperm energy production or acrosome reaction), fertilization, and/or early embryogenesis. Additionally, 20% have a known role in cellular process such as transcription regulation, protein transport, ubiquitin-like conjugation pathway, and lipid metabolism. The potential function of the remaining transcripts has yet to be defined.




Fig. 3. Analysis of treatment outcome as a function of required SREs. (A). Most of the 37 group II couples with all SREs present underwent TIC/UI, achieving an LB rate of 73% (22 of 30). The remaining samples reflecting patient preference along with the previously unsuccessful TIC/UI cases were treated by ART, achieving a 75% (9 of 12) LB rate. (B) RNA analysis from samples with at least one SRE absent. Note that only 3 of the 11 TIC/UI samples with an absent SRE achieved LB. The success ratio of LB using ART is similar to the ratio observed in samples with all SREs. (C) The percentage of LB using a noninvasive treatment for couples presenting with the complete set of SREs is higher compared to those with at least one SRE absent (two-tailed Fisher's exact test, $P = 0.012$).

SREs are absent in patients in whom ART was not successful. Their contribution to the mechanism of successful fertilization and early embryogenesis remains to be elucidated. It is possible that these RNAs are critical for implantation and/or embryogenesis, and thus, in these instances, even ART cannot lead to a viable pregnancy, which is perhaps exemplified by the absence of an SRE located within the gene for transcription factor *CAMTA2*.

RNA-seq data also afford the opportunity to SNP-genotype each population of sperm RNAs that may reflect a series of health modifiers (27). For example, within this initial study, 102 SREs were derived from 35 genes that have been associated with a spectrum of genetic disorders from enolase deficiency to Parkinson disease. This is of note given the global allelic imbalance in the gene expression favoring the paternal expression of these genes associated with complex diseases (28) that may be compounded when the paternal effect of diet and environment on the future health of the child is considered (29). Continued development of this sperm RNA-seq methodology is expected to reveal genomic variants from these data (27) that will better explain the underlying origins of male infertility and may help predict the future health of the child.

Table 2. Required SREs in the test group of samples (group III). The 648 RNA elements describing fertile sperm were tested in nine samples. (i) All samples that were obtained from an independent fertility clinic and achieved LB presented with all required SREs. LB was achieved spontaneously or by IUI for samples 4 and 5, whereas the remaining three cases (1 to 3) directly used ART. (ii) Samples with known female factor. A single instance (sample 6) shows the absence of two SREs as well as a known female factor. It is possible that with a GC (gestational carrier), the pregnancy was rescued by ART despite the absence of these two SREs.

	Treatment	Final outcome	Required SREs absent
(i) Samples from independent fertility clinic			
1	IVF (LB)	LB	0
2	IVF (NLB)/ICSI (LB)	LB	0
3	IVF (NLB)/ICSI (LB)	LB	0
4	IUI (LB)	LB	0
5	Natural conception	LB	0
(ii) Samples with known female factor			
6	ICSI (LB with GC)	LB	2
7	ICSI (NLB)/ICSI (LB with GC)	LB	0
8	ICSI (NLB)/ICSI (LB with GC)	LB	0
9	TIC (NLB)/IUI (NLB)	NLB	0

The use of spermatozoal RNA NGS identified a set of molecular biomarkers that shows potential to predict the success rate of fertility treatments. In comparison to a smaller microarray-based study where 26 differential RNAs were identified (18), NGS analysis identified 648 SREs, suggesting that RNA-seq technology may more completely resolve variances in RNA profiles for the complex sperm cell. The statistically significant differences observed in the outcomes of noninvasive treatments depending on the presence or absence of the complete set of SREs (two-tailed Fisher's test, $P = 0.012$) support the view that sperm RNA analysis has the potential to affect clinical care for idiopathic infertile couples when used to assess the likelihood of successful TIC/UI before using ART. This may permit an informed choice of a treatment paradigm that would help the female partner avoid undergoing invasive procedures such as egg collection. The results of this 0.7-powered study should encourage a larger, blinded, and controlled prospective analysis of patients using noninvasive treatments to ensure the utility of this prediction method before its introduction into the fertility clinic. With the rapidly decreasing cost of NGS, deep sequencing of sperm RNA has the distinct potential to produce clinical benefit and enhance our understanding of the father's contribution to the birth and life of a healthy child.

MATERIALS AND METHODS

Experimental design

A retrospective study was designed to investigate whether spermatozoal RNAs could predict the outcome of various fertility treatment options used in the care of idiopathic infertile couples. RNA sequencing

was used to obtain the spermatozoal RNA profile of patients included in the study. Several SREs required for natural conception were defined and tested using the sperm of idiopathic infertile males of couples that underwent noninvasive or invasive treatments. Sample size was dictated by the availability of patients matching the strict criteria in the fertility clinics, powering the study to 0.7 with an α error of 0.029.

Study subjects

Semen samples were collected after institutional review board (IRB) approval and informed consent from a total of 96 patients from the CREATe Fertility Centre, Toronto, Canada (site 1) and the Vincent Memorial Obstetrics and Gynecology Service, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA (site 2) and then processed and frozen at -80°C . Only couples presenting with infertility unexplained by standard procedures as confirmed by a reproductive endocrinologist and andrologist were recruited to the study. All participants underwent some reproductive treatment (TIC, IUI, IVF, or ICSI) because of their inability to achieve a successful LB by spontaneous conception. Noninvasive treatments (TIC and IUI) were the first fertility treatments used in about 80% of the patients, with a success rate of 65% in the first two cycles. After some unsuccessful IUI cycles (2.6 cycles on average), 26% of patients underwent ART treatments, achieving 85% success in the first cycle. The remaining 20% of patients made the initial personal treatment decision to directly undergo ART, with a success rate of 50% in the first cycle. Couples were excluded from this study if the male partner considerably deviated from the standard semen parameters. This included males presenting with less than 10 million motile sperm, indicating a decreased likelihood of successful IUI outcome (30). In addition, couples with a female partner exhibiting low ovarian reserve validated by anti-Müllerian hormone level <15.7 pM or known history of hormonal disorders, showing evidence of stage 3 or 4 endometriosis, a history of chemotherapy or pelvic irradiation, as well as patients unable or unwilling to consent were excluded from the study. Semen parameters were assessed as described in Supplementary Materials and Methods, and the day of semen evaluation was designated day 0. To minimize any potential effect on spermatozoal RNA by an external factor, we defined the control population (unassisted conception) as those couples achieving pregnancy in the first attempt of TIC within the first 90 days after sperm RNA analysis, corresponding to one complete spermatogenic cycle. The deidentified frozen samples were processed and analyzed at Wayne State University under the IRB protocols H-06-67-96 and HIC 095701MP2F.

RNA sequencing

Sperm RNA from 96 samples was isolated, quality-assessed, deep-sequenced, and analyzed as described in Supplementary Materials and Methods. The 72 samples that passed all sequence quality measures were divided into three groups for post hoc statistical analysis. Group I samples were used to determine the required SREs for “natural conception” LB. This positive control population was derived from seven couples that achieved an LB by controlling the optimal fertility window (TIC) during the first cycle monitored for intercourse timing. This was considered equivalent to natural conception. The abundance of all members of this composite group of SREs was assessed within the remaining 65 samples that underwent various fertility treatments. Group II test samples were composed of 55 couples, where 41 were initially treated by IUI or TIC. This included 22 couples that were suc-

cessfully treated by IUI, 3 couples that were successfully treated by TIC after the first spermatogenic cycle, and 4 couples that discontinued treatment (i), in contrast to 12 couples who underwent ART after unsuccessful IUI cycles (ii). The remaining 14 couples personally decided to undergo ART after semen assessment (iii). Group III test samples were composed of (i) samples from five couples from an independent fertility clinic, all of whom achieved an LB, and (ii) four likely female factor couples, three of whom only achieved an LB with a GC suggestive of a female factor and the fourth presenting with stage 2 endometriosis, a known female factor. The results corresponding to the 72 RNA-seq data sets are available at the Gene Expression Omnibus (GEO) [National Center for Biotechnology Information (NCBI)] repository (GSE65683).

Statistical analysis

Statistical analyses were performed using SigmaPlot version 11 (Systat Software), and statistical tests were considered significant at $P < 0.05$. According to the normality of the parameter tested (male and female ages, sperm motility, and DFI are normally distributed; total millions of sperm cells, sperm morphology, and number of SREs absent are not normally distributed), a parametric one-way ANOVA test or nonparametric Kruskal-Wallis one-way ANOVA by ranks ($\alpha = 0.05$) was used to detect differences in the average of different seminal parameters or SREs that were absent between the groups on the basis of the treatment used. According to the normality of the parameter tested, a parametric Student's t test or nonparametric Mann-Whitney U test (two-tailed, $\alpha = 0.05$) was used to detect differences in the average of different seminal parameters or SREs absent between the samples that achieved LB or failed (NLB) within each group. Two-tailed Fisher's exact test ($\alpha = 0.05$) was used to compare the success rate of different fertility treatments in the presence or absence of the complete set of SREs. G*Power version 3.1 was used to calculate the power of the two-tailed Fisher's exact test ($\alpha = 0.05$) (31).

SUPPLEMENTARY MATERIALS

www.sciencetranslationalmedicine.org/cgi/content/full/7/295/295re6/DC1
Materials and Methods

Fig. S1. Distribution and junctions of RNA-seq reads of a selected required SRE, *GPX4*.

Fig. S2. No correlation between the number of absent SREs and sperm parameters or partner age. References (32–43)

REFERENCES AND NOTES

1. J. Boivin, L. Bunting, J. A. Collins, K. G. Nygren, International estimates of infertility prevalence and treatment-seeking: Potential need and demand for infertility medical care. *Hum. Reprod.* **22**, 1506–1512 (2007).
2. Male Infertility Best Practice Policy Committee of the American Urological Association; Practice Committee of the American Society for Reproductive Medicine, Report on optimal evaluation of the infertile male. *Fertil. Steril.* **86**, S202–S209 (2006).
3. *2004 Assisted Reproduction Technology Success Rates: National Summary and Fertility Clinic Reports* (Centers for Disease Control and Prevention, Atlanta, GA, 2006).
4. G. M. Buck Louis, R. Sundaram, E. F. Schisterman, A. Sweeney, C. D. Lynch, S. Kim, J. M. Maisog, R. Gore-Langton, M. L. Eisenberg, Z. Chen, Semen quality and time to pregnancy: The Longitudinal Investigation of Fertility and the Environment Study. *Fertil. Steril.* **101**, 453–462 (2014).
5. L. van den Hoven, J. C. Hendriks, J. G. Verbeet, J. R. Westphal, A. M. Wetzels, Status of sperm morphology assessment: An evaluation of methodology and clinical value. *Fertil. Steril.* **103**, 53–58 (2015).
6. S. A. Krawetz, Paternal contribution: New insights and future challenges. *Nat. Rev. Genet.* **6**, 633–642 (2005).

7. G. D. Johnson, C. Lalancette, A. K. Linnemann, F. Leduc, G. Boissonneault, S. A. Krawetz, The sperm nucleus: Chromatin, RNA, and the nuclear matrix. *Reproduction* **141**, 21–36 (2011).
8. K. I. Aston, D. T. Carrell, Genome-wide study of single-nucleotide polymorphisms associated with azoospermia and severe oligozoospermia. *J. Androl.* **30**, 711–725 (2009).
9. F. Tüttelmann, M. Simoni, S. Kliesch, S. Ledig, B. Dworniczak, P. Wieacker, A. Röpke, Copy number variants in patients with severe oligozoospermia and Sertoli-cell-only syndrome. *PLoS One* **6**, e19426 (2011).
10. S. S. Hammoud, D. A. Nix, A. O. Hammoud, M. Gibson, B. R. Cairns, D. T. Carrell, Genome-wide analysis identifies changes in histone retention and epigenetic modifications at developmental and imprinted gene loci in the sperm of infertile men. *Hum. Reprod.* **26**, 2558–2569 (2011).
11. S. S. Hammoud, D. A. Nix, H. Zhang, J. Purwar, D. T. Carrell, B. R. Cairns, Distinctive chromatin in human sperm packages genes for embryo development. *Nature* **460**, 473–478 (2009).
12. J. Martínez-Heredia, S. de Mateo, J. M. Vidal-Taboada, J. L. Ballecà, R. Oliva, Identification of proteomic differences in asthenozoospermic sperm samples. *Hum. Reprod.* **23**, 783–791 (2008).
13. M. Jodar, S. Kalko, J. Castillo, J. L. Ballecà, R. Oliva, Differential RNAs in the sperm cells of asthenozoospermic patients. *Hum. Reprod.* **27**, 1431–1438 (2012).
14. A. E. Platts, D. J. Dix, H. E. Chemes, K. E. Thompson, R. Goodrich, J. C. Rockett, V. Y. Rawe, S. Quintana, M. P. Diamond, L. F. Strader, S. A. Krawetz, Success and failure in human spermatogenesis as revealed by teratozoospermic RNAs. *Hum. Mol. Genet.* **16**, 763–773 (2007).
15. R. Kläver, F. Tüttelmann, A. Bleiziffer, T. Haaf, S. Kliesch, J. Gromoll, DNA methylation in spermatozoa as a prospective marker in andrology. *Andrology* **1**, 731–740 (2013).
16. R. Azpiazu, A. Amaral, J. Castillo, J. M. Estanyol, M. Guimerà, J. L. Ballecà, J. Balasch, R. Oliva, High-throughput sperm differential proteomics suggests that epigenetic alterations contribute to failed assisted reproduction. *Hum. Reprod.* **29**, 1225–1237 (2014).
17. S. García-Herrero, N. Garrido, J. A. Martínez-Conejero, J. Remohí, A. Pellicer, M. Meseguer, Differential transcriptomic profile in spermatozoa achieving pregnancy or not via ICSI. *Reprod. Biomed. Online* **22**, 25–36 (2011).
18. N. Garrido, J. A. Martínez-Conejero, J. Jauregui, J. A. Horcajadas, C. Simón, J. Remohí, M. Meseguer, Microarray analysis in sperm from fertile and infertile men without basic sperm analysis abnormalities reveals a significantly different transcriptome. *Fertil. Steril.* **91**, 1307–1310 (2009).
19. C. Camprubí, M. Pladevall, M. Grossmann, N. Garrido, M. C. Pons, J. Blanco, Semen samples showing an increased rate of spermatozoa with imprinting errors have a negligible effect in the outcome of assisted reproduction techniques. *Epigenetics* **7**, 1115–1124 (2012).
20. M. Jodar, S. Selvaraju, E. Sandler, M. P. Diamond, S. A. Krawetz, Reproductive Medicine Network, The presence, role and clinical use of spermatozoal RNAs. *Hum. Reprod. Update* **19**, 604–624 (2013).
21. S. A. Krawetz, A. Kruger, C. Lalancette, R. Tagett, E. Anton, S. Draghici, M. P. Diamond, A survey of small RNAs in human sperm. *Hum. Reprod.* **26**, 3401–3412 (2011).
22. E. Sandler, G. D. Johnson, S. Mao, R. J. Goodrich, M. P. Diamond, R. Hauser, S. A. Krawetz, Stability, delivery and functions of human sperm RNAs at fertilization. *Nucleic Acids Res.* **41**, 4104–4117 (2013).
23. G. C. Ostermeier, D. Miller, J. D. Huntriss, M. P. Diamond, S. A. Krawetz, Reproductive biology: Delivering spermatozoan RNA to the oocyte. *Nature* **429**, 154 (2004).
24. A. A. Nardelli, T. Stafinski, T. Motan, K. Klein, D. Menon, Assisted reproductive technologies (ARTs): Evaluation of evidence to support public policy development. *Reprod. Health* **11**, 76 (2014).
25. Practice Committee of the American Society for Reproductive Medicine, Effectiveness and treatment for unexplained infertility. *Fertil. Steril.* **86**, S111–S114 (2006).
26. C. E. Malcolm, D. C. Cumming, Follow-up of infertile couples who dropped out of a specialist fertility clinic. *Fertil. Steril.* **81**, 269–270 (2004).
27. R. Piskol, G. Ramaswami, J. B. Li, Reliable identification of genomic variants from RNA-seq data. *Am. J. Hum. Genet.* **93**, 641–651 (2013).
28. J. J. Crowley, V. Zhabotynsky, W. Sun, S. Huang, I. K. Pakatci, Y. Kim, J. R. Wang, A. P. Morgan, J. D. Calaway, D. L. Aylor, Z. Yun, T. A. Bell, R. J. Buus, M. E. Calaway, J. P. Didion, T. J. Gooch, S. D. Hansen, N. N. Robinson, G. D. Shaw, J. S. Spence, C. R. Quackenbush, C. J. Barrick, R. J. Nonneman, K. Kim, J. Xenakis, Y. Xie, W. Valdar, A. B. Lenarcic, W. Wang, C. E. Welsh, C. P. Fu, Z. Zhang, J. Holt, Z. Guo, D. W. Threadgill, L. M. Tarantino, D. R. Miller, F. Zou, L. McMillan, P. F. Sullivan, F. Pardo-Manuel de Villena, Analyses of allele-specific gene expression in highly divergent mouse crosses identifies pervasive allelic imbalance. *Nat. Genet.* **47**, 353–360 (2015).
29. A. Soubry, C. Hoyo, R. L. Jirtle, S. K. Murphy, A paternal environmental legacy: Evidence for epigenetic inheritance through the male germ line. *Bioessays* **36**, 359–371 (2014).
30. W. Ombelet, N. Dhont, A. Thijssen, E. Bosmans, T. Kruger, Semen quality and prediction of IUI success in male subfertility: A systematic review. *Reprod. Biomed. Online* **28**, 300–309 (2014).
31. F. Faul, E. Erdfelder, A. G. Lang, A. Buchner, G*Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. *Behav. Res. Methods* **39**, 175–191 (2007).
32. *WHO Laboratory Manual for the Examination of Human Semen and Sperm-Cervical Mucus Interaction* (World Health Organization, Geneva, ed. 4, 1999).
33. H. Wolff, The biologic significance of white blood cells in semen. *Fertil. Steril.* **63**, 1143–1157 (1995).
34. *WHO Laboratory Manual for the Examination and Processing of Human Semen* (World Health Organization, Geneva, ed. 5, 2010).
35. T. F. Faul, S. B. Ackerman, K. F. Simmons, R. J. Swanson, S. S. Brugo, A. A. Acosta, A quick, reliable staining technique for human sperm morphology. *Arch. Androl.* **18**, 275–277 (1987).
36. D. P. Evenson, K. L. Larson, L. K. Jost, Sperm chromatin structure assay: Its clinical use for detecting sperm DNA fragmentation in male infertility and comparisons with other techniques. *J. Androl.* **23**, 25–43 (2002).
37. S. I. Moskvovtsev, J. Willis, J. White, J. B. Mullen, Sperm DNA damage: Correlation to severity of semen abnormalities. *Urology* **74**, 789–793 (2009).
38. S. Mao, R. J. Goodrich, R. Hauser, S. M. Schrader, Z. Chen, S. A. Krawetz, Evaluation of the effectiveness of semen storage and sperm purification methods for spermatozoa transcript profiling. *Syst. Biol. Reprod. Med.* **59**, 287–295 (2013).
39. R. Goodrich, G. Johnson, S. A. Krawetz, The preparation of human spermatozoal RNA for clinical analysis. *Arch. Androl.* **53**, 161–167 (2007).
40. S. Mao, E. Sandler, R. J. Goodrich, R. Hauser, S. A. Krawetz, A comparison of sperm RNA-seq methods. *Syst. Biol. Reprod. Med.* **60**, 308–315 (2014).
41. S. Lambard, I. Galeraud-Denis, G. Martin, R. Levy, A. Chocat, S. Carreau, Analysis and significance of mRNA in human ejaculated sperm from normozoospermic donors: Relationship to sperm motility and capacitation. *Mol. Hum. Reprod.* **10**, 535–541 (2004).
42. B. Langmead, C. Trapnell, M. Pop, S. L. Salzberg, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. *Genome Biol.* **10**, R25 (2009).
43. C. Trapnell, L. Pachter, S. L. Salzberg, TopHat: Discovering splice junctions with RNA-Seq. *Bioinformatics* **25**, 1105–1111 (2009).

Funding: The work was supported by a Collaborative Translational Research Project grant from EMD Serono to S.A.K. and M.P.D., funds to S.A.K. through Charlotte B. Failing Professorship, and NIH grants ES017285 and ES009718 to R.H. **Author contributions:** M.P.D., S.I.M., C.L.L., S.S., and R.H. provided and characterized the clinical samples used in the study. M.J. and R.G. isolated the sperm RNA and prepared the deep-sequencing libraries. E.S., M.J., and S.A.K. contributed to the bioinformatic analysis of the RNA-seq data and the interpretation of the results. The manuscript was collaboratively written by E.S., M.J., S.A.K., M.P.D., S.I.M., C.L.L., and R.H., and R.G., S.A.K., and M.P.D. directed the data analysis and writing and editing of the manuscript. All authors critically reviewed and approved the final version of the manuscript. **Competing interests:** S.A.K. received a speaker honorarium, and S.A.K. and M.P.D. received some research funding from EMD Serono. All other authors declare that they have no competing interests. **Data and materials availability:** RNA-seq data sets are available at the GEO (NCBI) repository (GSE65683).

Submitted 15 March 2015
Accepted 11 June 2015
Published 8 July 2015
10.1126/scitranslmed.aab1287

Citation: M. Jodar, E. Sandler, S. I. Moskvovtsev, C. L. Librach, R. Goodrich, S. Swanson, R. Hauser, M. P. Diamond, S. A. Krawetz, Absence of sperm RNA elements correlates with idiopathic male infertility. *Sci. Transl. Med.* **7**, 295re6 (2015).

Absence of sperm RNA elements correlates with idiopathic male infertility

Meritxell Jodar, Edward Sendler, Sergey I. Moskovtsev, Clifford L. Librach, Robert Goodrich, Sonja Swanson, Russ Hauser, Michael P. Diamond and Stephen A. Krawetz

Sci Transl Med 7, 295re6295re6.
DOI: 10.1126/scitranslmed.aab1287

Counting on the sperm RNA

Infertility affects many couples of reproductive age. Male infertility is typically evaluated by visual assessment of the sperm to determine sperm counts and morphological characteristics. Unfortunately, this approach is ineffective for patients whose sperm are morphologically normal, making it difficult to distinguish patients who require assisted reproductive technology from those who could benefit from cheaper and less invasive approaches. Jodar *et al.* have now identified a set of sperm RNA elements whose absence correlates with infertility, such that the more elements are lacking in a patient's sperm, the less likely he is to achieve fertility without technological assistance. If confirmed in prospective studies, these findings could help guide the selection of optimal fertility treatments for couples with idiopathic male infertility.

ARTICLE TOOLS

<http://stm.sciencemag.org/content/7/295/295re6>

SUPPLEMENTARY MATERIALS

<http://stm.sciencemag.org/content/suppl/2015/07/06/7.295.295re6.DC1>

RELATED CONTENT

<http://stm.sciencemag.org/content/scitransmed/6/249/249ra108.full>
<http://stm.sciencemag.org/content/scitransmed/5/212/212ra160.full>
<http://stm.sciencemag.org/content/scitransmed/3/92/92ps31.full>
<http://stm.sciencemag.org/content/scitransmed/3/92/92ra65.full>
<http://science.sciencemag.org/content/sci/350/6259/442.full>
<http://science.sciencemag.org/content/sci/350/6259/385.full>
<http://stm.sciencemag.org/content/scitransmed/8/336/336ra60.full>
<http://stm.sciencemag.org/content/scitransmed/8/336/336pc2.full>
<http://stm.sciencemag.org/content/scitransmed/8/353/353tc1.full>
<http://stm.sciencemag.org/content/scitransmed/8/353/353tr1.full>
<http://stm.sciencemag.org/content/scitransmed/9/372/eaag2959.full>
<http://stm.sciencemag.org/content/scitransmed/9/382/eaai7863.full>

REFERENCES

This article cites 38 articles, 1 of which you can access for free
<http://stm.sciencemag.org/content/7/295/295re6#BIBL>

PERMISSIONS

<http://www.sciencemag.org/help/reprints-and-permissions>

Use of this article is subject to the [Terms of Service](#)

Science Translational Medicine (ISSN 1946-6242) is published by the American Association for the Advancement of Science, 1200 New York Avenue NW, Washington, DC 20005. The title *Science Translational Medicine* is a registered trademark of AAAS.

Copyright © 2015, American Association for the Advancement of Science